Cargando…

Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease

BACKGROUND: The analysis of plasma cell-free DNA (cfDNA) is expected to provide useful biomarkers for early diagnosis of non-small-cell lung cancer (NSCLC). However, it remains unclear whether the intense release of cfDNA into the bloodstream of NSCLC patients results from malignancy or chronic infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Szpechcinski, A, Chorostowska-Wynimko, J, Struniawski, R, Kupis, W, Rudzinski, P, Langfort, R, Puscinska, E, Bielen, P, Sliwinski, P, Orlowski, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522634/
https://www.ncbi.nlm.nih.gov/pubmed/26125447
http://dx.doi.org/10.1038/bjc.2015.225
_version_ 1782383983111176192
author Szpechcinski, A
Chorostowska-Wynimko, J
Struniawski, R
Kupis, W
Rudzinski, P
Langfort, R
Puscinska, E
Bielen, P
Sliwinski, P
Orlowski, T
author_facet Szpechcinski, A
Chorostowska-Wynimko, J
Struniawski, R
Kupis, W
Rudzinski, P
Langfort, R
Puscinska, E
Bielen, P
Sliwinski, P
Orlowski, T
author_sort Szpechcinski, A
collection PubMed
description BACKGROUND: The analysis of plasma cell-free DNA (cfDNA) is expected to provide useful biomarkers for early diagnosis of non-small-cell lung cancer (NSCLC). However, it remains unclear whether the intense release of cfDNA into the bloodstream of NSCLC patients results from malignancy or chronic inflammatory response. Consequently, the current diagnostic utility of plasma cfDNA quantification has not been thoroughly validated in subjects with chronic respiratory inflammation. Here we assess the effect of chronic respiratory inflammation on plasma cfDNA levels and evaluate the potential clinical value of this phenomenon as an early lung cancer diagnostic tool. METHODS: We measured plasma cfDNA concentrations in 50 resectable NSCLC patients, 101 patients with chronic respiratory inflammation (chronic obstructive pulmonary disease, sarcoidosis, or asthma) and 40 healthy volunteers using real-time PCR. RESULTS: We found significantly higher plasma cfDNA levels in NSCLC patients than in subjects with chronic respiratory inflammation and healthy individuals (P<0.0001). There were no significant differences in plasma cfDNA levels between patients with chronic respiratory inflammation and healthy volunteers. The cutoff point of >2.8 ng ml(−1) provided 90% sensitivity and 80.5% specificity in discriminating NSCLC from healthy individuals (area under the curve (AUC)=0.90). The receiver-operating characteristics curve distinguishing NSCLC patients from subjects with chronic respiratory inflammation indicated 56% sensitivity and 91% specificity at the >5.25-ng ml(−1) cutoff (AUC=0.76). CONCLUSIONS: We demonstrated that elevated plasma cfDNA levels in NSCLC resulted primarily from tumour development rather than inflammatory response, raising the potential clinical implications for lung cancer screening and early diagnosis. Further research is necessary to better characterise and identify factors and processes regulating cfDNA levels in the blood under normal and pathological conditions.
format Online
Article
Text
id pubmed-4522634
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45226342016-07-28 Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease Szpechcinski, A Chorostowska-Wynimko, J Struniawski, R Kupis, W Rudzinski, P Langfort, R Puscinska, E Bielen, P Sliwinski, P Orlowski, T Br J Cancer Molecular Diagnostics BACKGROUND: The analysis of plasma cell-free DNA (cfDNA) is expected to provide useful biomarkers for early diagnosis of non-small-cell lung cancer (NSCLC). However, it remains unclear whether the intense release of cfDNA into the bloodstream of NSCLC patients results from malignancy or chronic inflammatory response. Consequently, the current diagnostic utility of plasma cfDNA quantification has not been thoroughly validated in subjects with chronic respiratory inflammation. Here we assess the effect of chronic respiratory inflammation on plasma cfDNA levels and evaluate the potential clinical value of this phenomenon as an early lung cancer diagnostic tool. METHODS: We measured plasma cfDNA concentrations in 50 resectable NSCLC patients, 101 patients with chronic respiratory inflammation (chronic obstructive pulmonary disease, sarcoidosis, or asthma) and 40 healthy volunteers using real-time PCR. RESULTS: We found significantly higher plasma cfDNA levels in NSCLC patients than in subjects with chronic respiratory inflammation and healthy individuals (P<0.0001). There were no significant differences in plasma cfDNA levels between patients with chronic respiratory inflammation and healthy volunteers. The cutoff point of >2.8 ng ml(−1) provided 90% sensitivity and 80.5% specificity in discriminating NSCLC from healthy individuals (area under the curve (AUC)=0.90). The receiver-operating characteristics curve distinguishing NSCLC patients from subjects with chronic respiratory inflammation indicated 56% sensitivity and 91% specificity at the >5.25-ng ml(−1) cutoff (AUC=0.76). CONCLUSIONS: We demonstrated that elevated plasma cfDNA levels in NSCLC resulted primarily from tumour development rather than inflammatory response, raising the potential clinical implications for lung cancer screening and early diagnosis. Further research is necessary to better characterise and identify factors and processes regulating cfDNA levels in the blood under normal and pathological conditions. Nature Publishing Group 2015-07-28 2015-06-30 /pmc/articles/PMC4522634/ /pubmed/26125447 http://dx.doi.org/10.1038/bjc.2015.225 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Molecular Diagnostics
Szpechcinski, A
Chorostowska-Wynimko, J
Struniawski, R
Kupis, W
Rudzinski, P
Langfort, R
Puscinska, E
Bielen, P
Sliwinski, P
Orlowski, T
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
title Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
title_full Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
title_fullStr Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
title_full_unstemmed Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
title_short Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
title_sort cell-free dna levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522634/
https://www.ncbi.nlm.nih.gov/pubmed/26125447
http://dx.doi.org/10.1038/bjc.2015.225
work_keys_str_mv AT szpechcinskia cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT chorostowskawynimkoj cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT struniawskir cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT kupisw cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT rudzinskip cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT langfortr cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT puscinskae cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT bielenp cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT sliwinskip cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease
AT orlowskit cellfreednalevelsinplasmaofpatientswithnonsmallcelllungcancerandinflammatorylungdisease